Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome
Open Access
- 24 November 2020
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2020, 1-16
- https://doi.org/10.1155/2020/4029062
Abstract
Background. Triple-negative breast cancer (TNBC) is usually poorly differentiated, highly invasive, susceptible to distant metastasis, and less responsive to endocrine and targeted therapy. However, immunotherapy is a promising treatment for TNBC patients recently. Methods. The prognostic value of immune-related genes (IRGs) was explored by using RNA sequencing and microarray data of 123 and 107 TNBC patients from TCGA and GEO databases, respectively. Results. In TCGA database, GO and KEGG pathway analysis of 119 differential IRGs indicated that they actively participate in the interaction of cytokines and receptors. A nomogram model constructed by the prognosis-related CCL25, IL29, TDGF3, GPR44, and GREM2 in the IRGs could personalize and visualize the 1-, 2-, 3-, 4-, and 5-year overall survival (OS) of TNBC patients. Moreover, TNBC patients could be defined as low-risk ( ) or high-risk (This publication has 33 references indexed in Scilit:
- T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancerBreast Cancer Research and Treatment, 2019
- Atezolizumab Combo Approved for PD-L1–positive TNBCCancer Discovery, 2019
- Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancerJournal for ImmunoTherapy of Cancer, 2019
- Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approachesBreast Cancer: Targets and Therapy, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from hereCancer, 2018
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategiesThe Lancet, 2016
- Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic CellsPLOS ONE, 2014
- A clinically relevant gene signature in triple negative and basal-like breast cancerBreast Cancer Research, 2011
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007